Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Juvenile Idiopathic Arthritis (JIA): full-pipeline trial registry
1 of 3 indexed Juvenile Idiopathic Arthritis (JIA) trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Juvenile Idiopathic Arthritis (JIA): 3 US clinical trials tracked, 1 recruiting.
Juvenile Idiopathic Arthritis (JIA) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 1 of these trials.
Enrollment posture brief
Registry condition juvenile-idiopathic-arthritis-jia
OPEN 1 | RECR 33% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Juvenile Idiopathic Arthritis (JIA) lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Juvenile Idiopathic Arthritis (JIA) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Juvenile Idiopathic Arthritis (JIA) is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
Oregon Health and Science University
NCT07065747
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
AbbVie
NCT03725007
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Amgen
NCT01544114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Juvenile Idiopathic Arthritis (JIA) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Juvenile Idiopathic Arthritis (JIA) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Juvenile Idiopathic Arthritis (JIA) page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Juvenile Idiopathic Arthritis (JIA) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Juvenile Idiopathic Arthritis (JIA) trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Juvenile Idiopathic Arthritis (JIA) condition card totals 3 registered trials; most-linked intervention Vimovo 500/20; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.